DAFTAR PUSTAKA

American Cancer Society: Cancer Facts and Figures (2018). Atlanta, Ga: American Cancer Society, 2018.

Amin, M. B., *et al*. (2017). AJCC Cancer Staging Manual, Eight Edition. *www.cancerstaging.org*, 563-581.

Ashida, A., Uhara, H., Kiniwa, Y., *et al*. (2012). Assessment of BRAF and KIT mutations in Japanese melanoma patients. *Journal of dermatological science*, *66*(3), 240-242.

Bachmann, I. M., Ladstein, R. G., Straume, O., *et al*. (2008). Tumor necrosis is associated with increased alpha, beta, integrin expression and poor prognosis in nodular cutaneous melanomas. *BMC cancer*, *8*(1), 362.

Bastian, B. C. (2014). The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. *Annual Review of Pathology: Mechanisms of Disease*, *9*, 239-271.

Bhatia, P., Friedlander, P., Zakaria, E. A., & Kandil, E. (2015). Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. *Annals of translational medicine*, *3*(2).

Buchbinder, E. I., & Desai, A. (2016). CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. *American journal of clinical oncology*, *39*(1), 98.

Bucheit, A. D., Syklawer, E., Jakob, J. A., *et al*. (2013). Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. *Cancer*, *119*(21), 3821-3829.

Chang, J. W. (2010). Cutaneous melanoma: Taiwan experience and literature review. *Chang Gung medical journal*, *33*(6), 602-612.

Chang, J. W. C., Guo, J., Hung, C. Y., *et al*. (2017). Sunrise in melanoma management: time to focus on melanoma burden in Asia. *Asia-Pacific Journal of Clinical Oncology*, *13*(6), 423-427.

Cherobin, A. C. F. P., Wainstein, A. J. A., Colosimo, E. A., *et al*. (2018). Prognostic factors for metastasis in cutaneous melanoma. *Anais brasileiros de dermatologia*, *93*(1), 19-26.

Clarke, L. E., Flake, D. D., Busam, K., *et al*. (2017). An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi. *Cancer*, *123*(4), 617-628.

Colt, D.G., Thompson, J.A., Albertini, M.R., *et al*. (2018). Melanoma. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).* 1-175.

Dickson, P. V., & Gershenwald, J. E. (2011). Staging and prognosis of cutaneous

melanoma. *Surgical Oncology Clinics*, *20*(1), 1-17.

Eggermont, A. M., Suciu, S., Testori, A., *et al*. (2012). Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. *European journal of cancer*, *48*(2), 218-225.

Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., *et al* (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *The lancet oncology*, *16*(5), 522-530.

Ehsani, L., Cohen, C., Fisher, K. E., & Siddiqui, M. T. (2014). BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression. *Applied Immunohistochemistry & Molecular Morphology*, *22*(9), 648-651.

Elder, D.E., Elenitasas, R., Murphy, G.F., *et al*. (2014). Benign pigmented lesions and malignant melanoma. Lever's Histo-Pathology of the Skin. *11th ed. Philadelphia*, 853–968.

Elder, D. E., Massi, D., Scolyer, R. A., & Willemze, R. (Eds.). (2018). *WHO classification of skin tumours*. International Agency for Research on Cancer, 65-77.

Gershenwald, J.E., Scolyer, R.A., Hess, K.R., *et al*. (2017). Melanoma of the skin. *American Joint Committee on Cancer.* AJCC Cancer Staging Manual, Eight Edition. *www.cancerstaging.org*, 563-581.

Gimotty, P. A., Van Belle, P., Elder, D. E., *et al*. (2005). Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. *Journal of Clinical Oncology*, *23*(31), 8048-8056.

Gray-Schopfer, V. C., Karasarides, M., Hayward, R., & Marais, R. (2007). Tumor necrosis factor-α blocks apoptosis in melanoma cells when BRAF signaling is inhibited. *Cancer research*, *67*(1), 122-129.

Homsi J., Kashani-Sabet M., Messina J.L., *et al*. (2005). Cutaneous Melanoma: Prognostic factors. *Cancer Control*, *12*(4), 223-229.

Hong, J. W., Lee, S., Kim, D. C., *et al.* (2014). Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: a preliminary study. *Annals of dermatology*, *26*(2), 195-202.

Hugdahl, E., Kalvenes, M. B., Puntervoll, H. E., *et*. (2016). BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. *British journal of cancer*, *114*(7), 801.

Humphrey, P. A., Dehner, L. P., & Pfeifer, J. D. (Eds.). (2008). *The Washington manual of surgical pathology*. Lippincott Williams & Wilkins, 503.

Jin, S. A., Chun, S. M., Choi, Y. D., *et al*. (2013). BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. *The Journal of investigative dermatology*, *133*(2), 579.

Kakavand, H., Walker, E., Lum, T., et al. (2016). BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. *Histopathology*, *69*(4), 680-686.

Kim, S. Y., & Yun, S. J. (2016). Cutaneous melanoma in Asians. *Chonnam medical journal*, *52*(3), 185-193.

Kong, B. Y., Carlino, M. S., & Menzies, A. M. (2016). Biology and treatment of BRAF mutant metastatic melanoma. *Melanoma management*, *3*(1), 33-45.

Ladstein, R. G., Bachmann, I. M., Straume, O., & Akslen, L. A. (2012). Tumor necrosis is a prognostic factor in thick cutaneous melanoma. *The American journal of surgical pathology*, *36*(10), 1477-1482.

LeBoit, P. E., Burg, G., Weedon, D., *et al*. (2006). World Health Organization Classification of Tumors. *Pathology and Genetics of Skin Tumors*, International Agency for Research on Cancer, 49-92.

Lee, H. Y., Chay, W. Y., Tang, M. B., *et al*. (2012). Melanoma: differences between Asian and Caucasian patients. *Ann Acad Med Singapore*, *41*(1), 17-20.

Lee, N., Zakka, L. R., Mihm Jr, M. C., & Schatton, T. (2016). Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. *Pathology*, *48*(2), 177-187.

Li, L. T., Jiang, G., Chen, Q., & Zheng, J. N. (2015). Ki67 is a promising molecular target in the diagnosis of cancer. *Molecular medicine reports*, *11*(3), 1566-1572.

Li, Y., Umbach, D. M., & Li, L. (2017). Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma. *Melanoma research*, *27*(6), 527-535.

Long, G. V., Menzies, A. M., Nagrial, A. M., *et al*. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *Journal of Clinical Oncology*, *29*(10), 1239-1246.

Meckbach, D., Bauer, J., Pflugfelder, A., *et al*. (2014). Survival according to BRAF-V600 tumor mutations–an analysis of 437 patients with primary melanoma. *PloS one*, *9*(1), e86194.

Muñoz-Couselo, E., García, J. S., Pérez-García, J. M., *et al*. (2015). Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. *Annals of translational medicine*, *3*(15).

Nurdjaja, V., Yozu, M., & Mathy, J. A. (2018). Essential components of melanoma histopathological reporting: The surgical oncologist's perspective. *Journal of skin cancer, 2018*.

Saint-Jean, M., Knol, A. C., Volteau, C., *et al*. (2018). Adoptive cell therapy with tumor-infiltrating lymphocytes in advanced melanoma patients. *Journal of immunology research, 2018*.

Sheen, Y. S., Liao, Y. H., Liau, J. Y., *et al*. (2016). Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. *Journal of the Formosan Medical Association*, *115*(2), 121-127.

Si, L., Kong, Y., Xu, X., *et al*. (2012). Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. *European journal of cancer*, *48*(1), 94-100.

Smalley, K. S. (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. *International journal of cancer*, *104*(5), 527-532.

Spagnolo, F., & Queirolo, P. (2012). Upcoming strategies for the treatment of metastatic melanoma. *Archives of dermatological research*, *304*(3), 177-184.

Tas, F., & Erturk, K. (2017). Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma. *International journal of dermatology*, *56*(2), 166-170.

Thiel, A., Moza, M., Kytölä, S., *et al*. (2015). Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma. *Human pathology*, *46*(2), 169-175.

Trinidad, C. M., Torres-Cabala, C. A., Curry, J. L., *et al*. (2019). Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. *Journal of clinical pathology*, *72*(4), 265-270.

Usman, H. A., Hernowo, B. S., Tobing, M. D. L., & Hindritiani, R. (2018). Result Analysis Of BRAF V600E Gene Mutation Using Molecular And Immunohistochemistry Detection In Acral Malignant Melanoma. *Asia Pacific Journal of Cancer Care*, *3*(3).

Ward, W. H., Lambreton, F., Goel, N., *et al*. (2017). Clinical presentation and staging of melanoma. In *Cutaneous Melanoma: Etiology and Therapy [Internet]*. Codon Publications.

Wood, K., & Luke, J. (2017). The Biology and Therapeutic Approach to BRAF Mutant Cutaneous Melanoma| PER. *American Journal of Hematology/Oncology®*, *13*(1).

Yamazaki, N., Tanaka, R., Tsutsumida, A., *et al*. (2015). BRAF V600 mutations and pathological features in Japanese melanoma patients. *Melanoma research*, *25*(1), 9.